Advisor Net Financial, Inc Biocryst Pharmaceuticals Inc Transaction History

Advisor Net Financial, Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 12, 2024	SELL	$4.89 - $7.65 $83 - $130	-17 Reduced 6.16%	259 $1,000
Q4 2023 Jan 19, 2024	BUY	$4.98 - $6.77 $44 - $60	9 Added 3.37%	276 $1,000
Q3 2023 Oct 12, 2023	SELL	$6.71 - $7.92 $73 - $87	-11 Reduced 3.96%	267 $1,000
Q2 2023 Jul 14, 2023	SELL	$6.96 - $8.81 $13 - $17	-2 Reduced 0.71%	278 $1,000
Q1 2023 Apr 28, 2023	BUY	$7.94 - $11.84 $111 - $165	14 Added 5.26%	280 $2,000
Q4 2022 Jan 13, 2023	BUY	$10.5 - $14.2 $73 - $99	7 Added 2.7%	266 $0
Q2 2022 Jul 07, 2022	SELL	$7.89 - $17.88 $11,835 - $26,820	-1,500 Reduced 85.28%	259 $3,000
Q1 2021 Apr 14, 2021	BUY	$7.37 - $13.61 $1,908 - $3,524	259 Added 17.27%	1,759 $18,000
Q4 2020 Feb 04, 2021	BUY	$3.37 - $8.61 $5,055 - $12,915	1,500 New	1,500 $11,000
Q4 2019 Feb 12, 2020	SELL	$1.59 - $3.45 $795 - $1,725	-500 Closed	0 $0
Q3 2019 Oct 23, 2019	BUY	$2.5 - $3.73 $1,250 - $1,865	500 New	500 $1,000

278

171M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.39B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Advisor Net Financial, Inc, based on Form 13F filings with the SEC.

Stay updated on Advisor Net Financial, Inc with notifications on news.